Delavirdine Dosage

Usual Adult Dose for HIV Infection

400 mg orally 3 times a day

Use: In combination with at least 2 other active antiretroviral agents, for the treatment of HIV-1 infection

Usual Pediatric Dose for HIV Infection

16 years or older: 400 mg orally 3 times a day

Use: In combination with at least 2 other active antiretroviral agents, for the treatment of HIV-1 infection

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Caution recommended.

Precautions

CONTRAINDICATIONS:

• Known hypersensitivity to any of the ingredients
• Coadministration with drugs highly dependent on CYP450 3A for clearance and for which elevated plasma levels are associated with serious and/or life-threatening events
• Coadministration with astemizole, terfenadine, dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride, pimozide, alprazolam, midazolam, triazolam

Safety and efficacy have not been established in patients younger than 16 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Comments:

• This drug is highly protein-bound; significant removal by dialysis is unlikely.

Other Comments

Administration advice:

• Use in combination with other antiretroviral drugs; do not use as monotherapy.
• May administer with or without food
• May disperse the 100 mg tablets in water before consuming; consume the dispersion promptly, rinse the glass with water, and then swallow the rinse to ensure consumption of the full dose.
• Administer the 200 mg tablets as whole tablets; do not disperse in water.
• Administer antacids at least 1 hour apart from this drug.
• In patients with achlorhydria: Administer this drug with an acidic beverage (e.g., orange or cranberry juice).

Storage requirements:

• Store at 20C to 25C (68F to 77F).
• Keep bottle tightly closed; protect from high humidity.

Reconstitution/preparation techniques:

• To prepare dispersion: Add four 100 mg tablets to at least 3 ounces of water, allow to stand for a few minutes, and then stir until the dispersion is uniform.

General:

• According to the Panel on Antiretroviral Guidelines for Adults and Adolescents, use of this drug is no longer recommended due to inferior virologic efficacy and inconvenient dosing.
• Before starting this drug in therapy-naive patients, the following should be considered:
• Insufficient data available directly comparing antiretroviral regimens containing this drug with currently preferred 3-drug regimens for initial HIV treatment.
• In studies comparing regimens consisting of 2 nucleoside reverse transcriptase inhibitors (NRTIs) (currently considered suboptimal) to this drug plus 2 NRTIs, the proportion of patients using the regimen containing this drug who achieved and sustained HIV-1 RNA level less than 400 copies/mL over 1 year of therapy was relatively low.
• Resistant virus emerges rapidly when this drug is used as monotherapy.

Patient advice:

• Read the US FDA-approved patient labeling (Patient Information).
• Stop this drug and notify physician if severe rash or rash with symptoms (e.g., fever, blistering, oral lesions, conjunctivitis, swelling, muscle/joint aches) occurs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer